Exane Derivatives Regenxbio Inc. Transaction History

Exane Derivatives

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 28, 2022	SELL	$30.19 - $40.28 $126,194 - $168,370	-4,180 Closed	0 $0
Q3 2021 Oct 26, 2021	SELL	$29.09 - $45.68 $9,483 - $14,891	-326 Reduced 7.23%	4,180 $175,000
Q2 2021 Jul 28, 2021	BUY	$32.46 - $40.48 $11,296 - $14,087	348 Added 8.37%	4,506 $175,000
Q1 2021 Apr 30, 2021	BUY	$33.61 - $49.95 $6,722 - $9,990	200 Added 5.05%	4,158 $141,000
Q4 2020 Jan 27, 2021	BUY	$26.52 - $49.35 $21,560 - $40,121	813 Added 25.85%	3,958 $179,000
Q3 2020 Oct 06, 2020	BUY	$27.01 - $40.26 $11,641 - $17,352	431 Added 15.88%	3,145 $86,000
Q2 2020 Jul 10, 2020	BUY	$27.75 - $43.44 $74,925 - $117,288	2,700 Added 19285.71%	2,714 $99,000
Q1 2019 Apr 24, 2019	SELL	$40.82 - $62.45 $10,286 - $15,737	-252 Reduced 94.74%	14 $0
Q3 2018 Oct 24, 2018	SELL	$65.0 - $82.15 $242,710 - $306,748	-3,734 Reduced 93.35%	266 $0
Q1 2018 Apr 30, 2018	BUY	$24.05 - $37.5 $96,200 - $150,000	4,000 New	4,000 $0

196

43M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $329M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.